• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Caduet (amlodipine besylate and atorvastatin calcium tablet)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Caduet (amlodipine besylate and atorvastatin calcium tablet)

  • Profile

Profile

Contact Information

Contact: Viatris
Website: https://www.caduet.com/

Currently Enrolling Trials

    Show More

    General Information

    Caduet  is a combination of amlodipine besylate, a calcium channel blocker, and atorvastatin calcium, a HMG CoA-reductase inhibitor.

    Caduet is specifically indicated for:

    • the treatment of hypertension, to lower blood pressure
    • the treatment of Coronary Artery Disease 
    • as an adjunct therapy to diet for prevention of cardiovascular disease and hyperlipidemia

    The recommended dose is:

    Amlodipine: Usual starting dose is 5mg/day. Maximum dose is 10 mg/day. Start small adults or children, fragile, or elderly patients, or patients with hepatic insufficiency on 2.5 mg once daily.

    Atorvastatin: Usual starting dose is 10-20 mg/day. Maximum dose is 80 mg/day. Start patients requiring large LDL-C reduction (> 45%) at 40 mg once daily.

    Mechanism of Action

    Amlodipine, a long acting calcium ion antagonist, is the active ingredient in Norvasc (Pfizer) and Lotrel (Novartis). Amlodipine inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. The drug binds to dihydropyridine and nondihydropyridine binding sites. In addition, amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure.

    Atorvastatin, a HMGCoA reductase inhibitor indicated for lowering cholesterol, is the active ingredient in Lipitor (Pfizer). Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMGCoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell-surface to enhance uptake and catabolism of LDL.

    Side Effects

    Adverse events associated with the use of Caduet may include (but are not limited to) the following:

    • Headache
    • Abdominal Pain
    • Rash
    • Chest pain,
    • Nausea
    • Insomnia
    • Dizziness

    Clinical Trial Results

    FDA approval of Caduet was based on a double-blind, placebo-controlled study enrolling 1,600 subjects with co-morbid hypertension and dyslipidemia. Results showed that all combination-treatment groups of amlodipine and atorvastatin demonstrated statistically significant dose-related reductions in systolic blood pressure (SBP), Diastolic Blood pressure (DBP) and LDL-C compared to placebo.

    Subjects received once daily treatment with eight dose combinations of amlodipine and atorvastatin (5/10, 10/10, 5/20, 10/20, 5/40, 10/40, 5/80, or 10/80mg), amlodipine alone (5 mg or 10 mg), atorvastatin alone (10 mg, 20 mg, 40 mg, or 80 mg) or placebo.

    Approval Date: 2004-01-01
    Company Name: Viatris
    Back to Listings

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing